🟢 New in Current Filing RISK FACTORS 🔒

🟢 New in Current Filing China’s Ministry of Commerce has added Illumina to its List of Unreliable Entities, which could result in fines or restrictions on our ability to do business in China and could have a material adverse effect on our revenue and results of operations. 🔒

🟢 New in Current Filing Uncertainties with respect to the development, deployment, and use of artificial intelligence in our business and products may result in harm to our business and reputation. 🔒

🟢 New in Current Filing On June 24, 2024, we completed the separation of GRAIL into a separate, independent publicly traded company. As of September 6, 2024, all previously disclosed regulatory proceedings in the United States and European Union related to our acquisition of GRAIL (the Acquisition) have come to an end. Litigation, regulation, and other proceedings related to or resulting from the Acquisition have resulted in operational restrictions and increased costs and could result in similar additional future consequences or further result in loss of revenues. 🔒

🟢 New in Current Filing The Spin-Off could result in substantial tax liability. 🔒

🟢 New in Current Filing Following the Spin-Off, we remain the obligor on the contingent value rights (the CVRs) we issued in connection with the GRAIL Acquisition. 🔒

🟢 New in Current Filing The Spin-Off could adversely affect the market value of the CVRs. 🔒

🟢 New in Current Filing Changes in, or failure to comply with, competition laws could adversely affect our business, financial condition, or results of operations. 🔒

🟢 New in Current Filing Purchases of Equity Securities by the Issuer 🔒

🟢 New in Current Filing the Program 🔒

🟢 New in Current Filing (Accumulated 🔒

🟢 New in Current Filing 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIESBusiness Overview 🔒

🟢 New in Current Filing Accounting Pronouncements Adopted in 2024 🔒

🟢 New in Current Filing Revenue Recognition 🔒

🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟢 New in Current Filing Derivative Financial Instruments 🔒

🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟢 New in Current Filing Revenue by Source 🔒

🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟢 New in Current Filing 5. GOODWILL, INTANGIBLE ASSETS, AND ACQUISITIONSGoodwill 🔒

🟢 New in Current Filing 2024 Impairment of Goodwill 🔒

🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟢 New in Current Filing 2023 Impairment of Goodwill 🔒

🟢 New in Current Filing 4.650% Term Notes due 2026 (2026 Term Notes) 🔒

🟢 New in Current Filing Delayed Draw Term Loan due 2025 🔒

🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟢 New in Current Filing Books and Records Action 🔒

🟢 New in Current Filing 12. SEGMENT AND GEOGRAPHIC INFORMATIONReportable Segment Information 🔒

🟢 New in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟢 New in Current Filing Supplemental Information 🔒

🟢 New in Current Filing POWER OF ATTORNEY 🔒

🔴 No Match in Current Filing RISK FACTORS 🔒

🔴 No Match in Current Filing We are subject to various uncertainties and restrictions while the Acquisition remains subject to ongoing regulatory and legal review and proceedings related thereto, including the EC Divestment Decision, that could adversely affect our business, financial condition and results of operations. 🔒

🔴 No Match in Current Filing The market price of our common stock may decline as a result of the Acquisition and the final outcomes of the regulatory and judicial reviews thereof. 🔒

🔴 No Match in Current Filing Purchases of Equity Securities by the Issuer 🔒

🔴 No Match in Current Filing Business Overview 🔒

🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🔴 No Match in Current Filing Cash Equivalents 🔒

🔴 No Match in Current Filing Business Combinations 🔒

🔴 No Match in Current Filing Acquisition of GRAIL, Inc. 🔒

🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🔴 No Match in Current Filing 0% Convertible Senior Notes due 2023 (2023 Convertible Notes) 🔒

🔴 No Match in Current Filing Purchase Obligations 🔒

🔴 No Match in Current Filing Employee Separation Costs (1) 🔒

🔴 No Match in Current Filing Other (Expense) Income, Net 🔒

🔴 No Match in Current Filing Acquisition of GRAIL 🔒

🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🔴 No Match in Current Filing Reportable Segment Information 🔒

🔴 No Match in Current Filing Core Illumina: 🔒

🔴 No Match in Current Filing NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified Fiscal Year 🔒

🟡 Modified Concentrations of Risk 🔒

🟡 Modified Revenue by Geographic Area 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified Opinion on the Financial Statements 🔒

🟡 Modified Performance Obligations 🔒

🟡 Modified Retirement Plan 🔒

🟡 Modified Research and Development 🔒

🟡 Modified Accounting Pronouncements Adopted in 2022 🔒

🟡 Modified Provision for Income Taxes 🔒

🟡 Modified Our products, if used for the diagnosis of disease, could be subject to government regulation, and the regulatory approval and maintenance process for such products may be expensive, time-consuming, and uncertain both in timing and in outcome. Since our strategy includes an emphasis on increasing our participation in clinical markets, we will be increasingly exposed to these risks. 🔒

🟡 Modified Stock Options 🔒

🟡 Modified Marketable Equity Securities 🔒

🟡 Modified Helix Contingent Value Right 🔒

🟡 Modified Contract Assets and Liabilities 🔒

🟡 Modified Goodwill, Intangible Assets and Other Long-Lived Assets 🔒

🟡 Modified Advertising Costs 🔒

🟡 Modified In the past, defects have been discovered in our products, as a result of which we have incurred costs and our products have been subject to recalls. If defects are discovered in our products in the future, we may incur additional unforeseen costs, our products may be subject to recalls, customers may not purchase our products, our reputation may suffer, and ultimately our sales and operating earnings could be negatively impacted. 🔒

🟡 Modified GRAIL Contingent Consideration 🔒

🟡 Modified Financial Statement Schedules 🔒

🟡 Modified Property and Equipment 🔒

🟡 Modified RECENT ACCOUNTING PRONOUNCEMENTS 🔒

🟡 Modified Cash Equivalents and Investments 🔒

🟡 Modified Employee Stock Purchase Plan 🔒

🟡 Modified Cash Flow Summary 🔒

🟡 Modified 2022 Impairment of Goodwill 🔒

🟡 Modified Business Combinations 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified (In millions) 🔒

🟡 Modified Income Taxes 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified 0% Convertible Senior Notes due 2023 (2023 Convertible Notes) 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified Other Liability-Classified Awards 🔒

🟡 Modified Employee Separation Costs 🔒

🟡 Modified Restructuring 🔒

🟡 Modified Non-Marketable Equity Securities 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified Stock Units 🔒

🟡 Modified ADOPTIONS, MODIFICATIONS OR TERMINATIONS OF TRADING PLANS 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified Shareholder Derivative Complaints 🔒

🟡 Modified Loss per Share 🔒

🟡 Modified LIQUIDITY AND CAPITAL RESOURCES 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified Accounting Pronouncements Pending Adoption 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified (In millions, except par value) 🔒

🟡 Modified 6. DEBT AND OTHER COMMITMENTSSummary of Term Debt Obligations 🔒

🟡 Modified Fair Value Measurements 🔒

🟡 Modified Restricted Stock 🔒

🟡 Modified Financial Overview 🔒

🟡 Modified MARKET INFORMATION 🔒

🟡 Modified Acquisition of GRAIL 🔒

🟡 Modified Critical Audit Matters 🔒

🟡 Modified Performance Stock Options(1) 🔒

🟡 Modified Contingent Consideration Liabilities 🔒

🟡 Modified CONSOLIDATED FINANCIAL STATEMENTS 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified Accrued Liabilities 🔒

🟡 Modified About Illumina 🔒

🟡 Modified Purchase Obligations 🔒

🟡 Modified Securities Class Actions 🔒

🟡 Modified Revolving Credit Agreement 🔒

🟡 Modified Venture Funds 🔒

🟡 Modified Intangible Assets 🔒

🟡 Modified Impairment assessment of GRAIL in-process research and development (IPR&D) 🔒

🟡 Modified (In millions, except per share amounts) 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified (In millions) 🔒

🟡 Modified Spin-Off of GRAIL (see Note 2) 🔒

🟡 Modified Property and Equipment 🔒

🟡 Modified RESULTS OF OPERATIONS 🔒

🟡 Modified Geographic Data 🔒

🟡 Modified Share-Based Compensation 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified Operating Expense 🔒

🟡 Modified 4.35% - 5.54% 🔒

🟡 Modified 10. INCOME TAXES 🔒

🟡 Modified Share-Based Compensation 🔒

🟡 Modified NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued) 🔒

🟡 Modified Other Income (Expense) 🔒

🟡 Modified In April 2024, the FDA issued the Final Rule relating to Laboratory Development Tests (LDTs). Newly developed LDT products may be subject to regulatory clearance or approval, and could result in adverse impacts to our business, financial condition, or results of operations. 🔒

🟡 Modified Gross Margin 🔒

🟡 Modified Our acquisitions expose us to risks that could adversely affect our business, and we may not achieve the anticipated benefits of acquisitions of businesses or technologies. 🔒

🟡 Modified 8. SUPPLEMENTAL BALANCE SHEET DETAILSAccounts Receivable 🔒

🟡 Modified Share Repurchases 🔒